1/13
08:01 am
jazz
Jazz Pharmaceuticals price target raised to $235 from $210 at Needham [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals price target raised to $235 from $210 at Needham [Yahoo! Finance]
1/12
11:50 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Truist Financial Corporation from $220.00 to $230.00. They now have a "buy" rating on the stock.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Truist Financial Corporation from $220.00 to $230.00. They now have a "buy" rating on the stock.
1/12
08:04 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Needham & Company LLC from $210.00 to $235.00. They now have a "buy" rating on the stock.
Medium
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Needham & Company LLC from $210.00 to $235.00. They now have a "buy" rating on the stock.
1/11
08:11 am
jazz
Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain [Yahoo! Finance]
Low
Report
Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain [Yahoo! Finance]
1/10
07:35 pm
jazz
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Weakness [Yahoo! Finance]
Low
Report
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Weakness [Yahoo! Finance]
1/9
02:03 pm
jazz
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology [Seeking Alpha]
Low
Report
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology [Seeking Alpha]
1/8
04:37 pm
jazz
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer [Yahoo! Finance]
1/8
04:05 pm
jazz
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
Low
Report
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
1/8
08:02 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
1/6
02:03 pm
jazz
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit [Yahoo! Finance]
Low
Report
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit [Yahoo! Finance]
1/6
02:01 pm
jazz
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA [Yahoo! Finance]
Low
Report
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA [Yahoo! Finance]
1/6
01:32 pm
jazz
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
Low
Report
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
12/19
01:33 am
jazz
Is It Too Late To Consider Jazz Pharmaceuticals After Its Strong 2024 Share Price Rally? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider Jazz Pharmaceuticals After Its Strong 2024 Share Price Rally? [Yahoo! Finance]
12/17
04:55 pm
jazz
Jazz Pharmaceuticals to Participate in Upcoming Investor Events [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals to Participate in Upcoming Investor Events [Yahoo! Finance]
12/17
04:15 pm
jazz
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
Low
Report
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
12/17
04:15 pm
jazz
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
Low
Report
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
12/12
04:58 am
jazz
3 Value Stocks We're Skeptical Of [Yahoo! Finance]
Low
Report
3 Value Stocks We're Skeptical Of [Yahoo! Finance]
12/10
07:21 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/6
07:51 am
jazz
Why Analysts Think Jazz Pharmaceuticals Story Is Changing After New Ziihera Growth Outlook [Yahoo! Finance]
Low
Report
Why Analysts Think Jazz Pharmaceuticals Story Is Changing After New Ziihera Growth Outlook [Yahoo! Finance]
12/5
09:18 am
jazz
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting [Yahoo! Finance]
12/5
09:00 am
jazz
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Low
Report
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
12/3
04:31 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
12/2
04:26 pm
jazz
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium [Yahoo! Fina
Low
Report
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium [Yahoo! Fina
12/2
04:05 pm
jazz
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Low
Report
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
11/27
07:07 pm
jazz
A Look at Jazz Pharmaceuticals's Valuation After Breakthrough Phase 3 Ziihera Trial Results [Yahoo! Finance]
Low
Report
A Look at Jazz Pharmaceuticals's Valuation After Breakthrough Phase 3 Ziihera Trial Results [Yahoo! Finance]